Article: Nicotinamide Riboside and Pterostilbene Reduce Liver Inflammation in NAFLD: Clinical Findings

Nov 22, 2022 Clinical Inflammation Liver Disease Liver Health

Nicotinamide Riboside and Pterostilbene Reduce Liver Inflammation in NAFLD: Clinical Findings

Objectives

To determine the effects of nicotinamide riboside and pterostilbene (NRPT) supplementation on liver fat in adults with non-alcoholic fatty liver disease (NAFLD).

Journal

Hepatology

Key Outcomes

NRPT supplementation did not reduce liver fat. However, NRPT reduced markers of liver inflammation, including alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT).

Duration

6.5 months

Dose

250 or 500 mg NR + 50 or 100 mg PT

Study Design

Randomized, double-blind, placebo-controlled, parallel assignment study in 111 adults with NAFLD

See Published Study

Cellular Health

Autophagy Promotes Cell Survival by Maintaining Stable NAD+ Levels: Preclinical Findings

SynopsisAutophagy is a cellular process that removes damaged parts of the cell and is important for healthy aging. When autophagy is lost, NAD+ levels fall due to increased activity of enzymes that...

Metabolic Health

Combination of Metabolic Cofactors and Nicotinamide Riboside Reduces Obesity and Insulin Resistance: Preclinical Findings

SynopsisObesity is a global health problem marked by excessive fat that often leads to metabolic issues like insulin resistance, high blood pressure, abnormal cholesterol levels, and metabolic synd...